Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 14/20 | 0.52 |
| ▸ | CLK2 | P49760 | 8/20 | 0.52 |
| ▸ | CLK3 | P49761 | 8/20 | 0.52 |
| ▸ | WNT1 | P04628 | 9/20 | 0.51 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.50 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5386655 | 0.83 | CSNK1D (0.72) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL5381396 | 0.82 | CSNK1D (0.48) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL5394703 | 0.81 | CSNK1D (0.53) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL5388950 | 0.80 | MAP2K4 (0.54) | DYRK1ACLK2CLK3WNT1MAP2K4 | |
| SCHEMBL13876986 | 0.80 | CSNK1D (0.61) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL13812056 | 0.80 | CSNK1D (0.51) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL8257531 | 0.77 | CSNK1D (0.44) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL5381928 | 0.76 | CSNK1D (0.49) | DYRK1AWNT1CSNK1D | |
| SCHEMBL8256328 | 0.76 | CSNK1D (0.44) | DYRK1ACLK2CLK3WNT1CSNK1D | |
| SCHEMBL5377200 | 0.74 | NTRK1 (0.53) | DYRK1ACLK2CLK3WNT1MAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | claimed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | claimed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-7211594-B2 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-05-01 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | SIGNAL PHARMACEUTICALS, LLC | 2007-03-15 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2005-01-13 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | SIGNAL PHARMACEUTICALS, LLC | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127536-A1 | Methods for treating an inflammatory condition or inhibiting JNK | MAPK1, MAP3K1, MAPKAPK2 | DYRK1A 1188/4885CLK2 352/4885CLK3 527/4885 |
| US-20070060616-A1 | Methods for treating, preventing and managing chronic lymphocytic leukemia with indazole compounds | BCL9, MCL1, INMT | DYRK1A 1932/4885CLK2 182/4885CLK3 226/4885 |
| US-20050009876-A1 | Indazole compounds, compositions thereof and methods of treatment therewith | GPR119, JAK3, IGF1R | DYRK1A 426/4885CLK2 398/4885CLK3 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.